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Measuring quality of life among people
living with HIV: a systematic review of
reviews
Vanessa Cooper1* , Jane Clatworthy1, Richard Harding2, Jennifer Whetham1 and Emerge Consortium
Abstract
Aim: A systematic review of reviews was conducted to identify and appraise brief measures of health-
related quality of life (HRQoL) that have been used in peer-reviewed research with people living with HIV.
Methods: The review was conducted in two stages: 1) search of electronic databases to identify systematic reviews
of tools used to measure HRQoL in adults living with HIV, published since the year 2000; 2) selection of HRQol
scales from those identified in the reviews. Inclusion criteria included scales that could be self-administered in
10 min or less, covering at least 3 domains of quality of life (physical function, social/role function and mental/
emotional function). For generic scales, inclusion criteria included the availability of normative data while for HIV-
specific scales, patient input into the development of the scale was required.
Results: Ten reviews met the inclusion criteria. Nine generic scales met the inclusion criteria: the EuroQol five
dimensions questionnaire (EQ-5D); Health Utilities Index; McGill Quality of Life questionnaire; Medical Outcomes
Study (MOS) Short Form (SF)-12; SF-36; World Health Organisation Quality of Life (WHOQOL- BREF), Questions of Life
Satisfaction (FLZM) and SF-20. Available psychometric data supported the EQ-5D and SF-36. Seven HIV-specific
scales met the inclusion criteria: the AIDS Clinical Trials Group (ACTG)-21; HIV-QL-31; MOS-HIV; Multidimensional
Quality of Life Questionnaire for Persons with HIV/AIDS (MQOL-HIV), PROQOL-HIV, Symptom Quality of Life
Adherence (HIV-SQUAD) and the WHOQOL-HIV BREF. Of the HIV -specific measures, the MOS-HIV was considered to
have the most well-established psychometric properties, however limitations identified in the reviews included
insufficient input from people living with HIV in the development of the scale, cross-cultural relevance and continued
applicability. Two relatively new measures, the WHOQOL-HIV BREF and PROQOL-HIV, were considered to have
promising psychometric properties and may have more relevance to people living with HIV.
Conclusion: The findings highlight the need for further validation of HRQoL measures in people living with HIV. The
choice of one measure over another is likely to be influenced by the purpose of the quality of life assessment and the
domains of HRQoL that are most relevant to the specific research or clinical question.
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Background
Combination antiretroviral therapy (ART) has changed
HIV from a terminal disease to a chronic condition in
countries where treatment is widely available. With ap-
propriate treatment, people with HIV can now have a
near-normal life-expectancy [1]. However, people with
HIV continue to have substantially lower health-related
quality of life (HRQoL) than the general population,
even where the majority of those living with HIV have
virological control and are immunologically stable [2].
Evidence suggests that in addition to the underlying
infection, social circumstances, relationship issues,
comorbidities and stigma may impact on HRQoL in
people with HIV [3].
HRQoL is a multidimensional construct concerned
with the impact of health on an individual’s perception
of their wellbeing and level of functioning in import-
ant areas of their life [4]. There is a lack of consensus
regarding the specific dimensions of quality of life [5].
The constitution of the World Health Organisation,
adopted in 1946, states that “Health is a state of
complete physical, mental and social well-being” [6].
Reflecting this, health related quality of life is often
conceptualised as having physical, mental and social
domains [7]. Concepts such as independence, spiritu-
ality and environmental factors are also considered
relevant [8].
Improving quality of life is central to the care and
support of people with HIV [9]. Evaluations of new
treatments and interventions to improve healthcare
require the measurement of HRQoL as well as clinical
endpoints (CD4 count, viral load, progression to
AIDS). Valid, reliable and responsive tools are re-
quired to evaluate the impact of these interventions
on HRQoL. To date there have been a number of re-
views conducted to identify and assess measures of
HRQoL in people with HIV, but these reviews have
had diverse aims. For example, some have looked only
at specific pre-selected measures (MOS-HIV and EQ-
5D [10]) or measures that have been applied in a
specific context (e.g. clinical trials [4, 11], developed
countries [12], or sub-Saharan Africa [13]). The aim of
this review is to identify brief, validated, pragmatic
tools for appropriate assessment of HRQoL in HIV in-
terventions and routine clinical care. It was not our
intention to analyse the measurement properties of
HRQoL tools, but to synthesise the findings of existing
reviews.
Method
The methodology was based on published recommenda-
tions for conducting systematic reviews of reviews [14].
As there was no specific guidance available for reporting
on systematic reviews of reviews, the PRISMA guidelines
[15] were used as a guide.
Search strategy
Papers were identified in two ways:
1) Four online databases (Cochrane Database of
Systematic Reviews, Database of Abstracts of
Reviews of Effects, Medline, PsycINFO) were
searched using the terms listed in Table 1.
2) Hand searching of reference lists of reviewed papers.
The searches were conducted in February 2016. Searches
were limited to studies published since year 2000. No
language limits were set at this stage.
References of identified articles were exported to
EndNote and deduplicated. The references and ab-
stracts were then exported into an Excel spreadsheet
for abstract review. All abstracts were reviewed inde-
pendently by two researchers (JC, VC) to identify po-
tentially relevant papers. Disagreement was resolved
through discussion and adjudication by RH and JW.
Full text copies of papers that appeared relevant were
obtained and subjected to further scrutiny by the two
reviewers.
Inclusion and exclusion criteria
Papers were included in the review if they met the fol-
lowing criteria:
Inclusion criteria
Criterion 1: the paper reviewed tools that had been used
to measure quality of life among adults living with HIV.
Criterion 2: the paper reported findings from a litera-
ture review that reported a systematic search strategy.
Exclusion criteria
Criterion 1: the review reported on HRQoL measures in
children/adolescents.
Criterion 2: the review was published prior to 2000.
We were interested in the assessment of quality of life of
people living with HIV after the introduction of highly
active antiretroviral therapy (HAART) in 1996. The year
2000 was selected to allow for the conduct and publica-
tion of both individual empirical articles and subsequent
review papers capturing HRQoL in the HAART era.
Criterion 3: conference abstract
Criterion 4: focused on quality of life in relation to a spe-
cific comorbidity/ treatment side effects (e.g. lipodystrophy).
Analysis
The search was recorded using the PRISMA flowchart
[15]. Two researchers (JC, VC) independently extracted
the following data from the papers, where available: the
Cooper et al. Health and Quality of Life Outcomes  (2017) 15:220 Page 2 of 20
aim of the review, dates of the search, databases and other
sources searched, search terms, language restrictions, the
number of papers reviewed, the generic and HIV-specific
HRQoL measures identified.
In order to assess the quality of the reviews, two re-
viewers (JC, VC) independently applied existing quality
criteria [16] that assess: 1) research question 2) eligibil-
ity criteria 3) search strategy, 4) selection of papers, 5)
quality assessment 6) presentation of data 7) publication
bias 8) heterogeneity. Disagreement was resolved through
discussion.
Inclusion of HRQoL measures for the review
The second stage of the review involved the selection
of appropriate HRQoL measures from those identified
in the reviews. A similar approach to that taken by
Clayson et al. (2006) [4] was adopted, in order to
identify comprehensive yet pragmatic tools for asses-
sing HRQoL in HIV interventions and clinical care.
Measures were deemed appropriate if they met the
following criteria:
– Content: Coverage of at least three core domains of
HRQoL: physical function, social/role function and
mental/emotional health. In addition patient input
was required in the development of HIV-specific
measures, in order to reflect patients’ experience of
disease.
– Practicality: Measures needed to be self-
administered and typically completed within
10 min. Where completion time data were not
available, we included measures with less than 40
items. This cut-off was based on an estimation of
completion rates drawing on the data available in
the reviews, indicating approximately four items
per minute.
– Normative data: For generic measures, normative data
needed to be available to allow comparison between
people with HIV and the general population.
Information on each of the selected measures was
then obtained from the reviews. This included the
HRQoL domains addressed, number of items, type of
scale, accessibility (e.g. availability in different lan-
guages, availability of population preference rates for
generic measures, approximate time taken to complete
the measure), reliability, validity (including responsive-
ness) and conclusions/recommendations made within
the reviews.
Results
Figure 1 shows the PRISMA flowchart. The electronic
database search identified 544 papers. After removal
of duplicates, 278 abstracts were subjected to review.
After applying our inclusion and exclusion criteria, 27
articles were obtained and subjected to full text
review. Of those, 9 met the inclusion criteria. One
further study was identified through the reference list
search.
Overview of the published systematic reviews
Characteristics of the reviews are summarised in Table 2.
The search periods for the published systematic reviews
addressed the period 1995–2013 (6 studies did not rec-
ord the dates of the search and one study did not record
the start date). Four reviews were restricted to abstracts/
papers published in the English language [3, 10–12], one
was restricted to papers published in English or Spanish
[17], one had no language restrictions [18] and the
remaining 4 reviews did not state whether or not the
review was restricted by language [4, 13, 19, 20]. The
number of articles reviewed ranged from 26 to 852 (six
did not specify the number of articles reviewed). The
number of generic HRQoL measures identified by the
reviews ranged from 0 to 23 (median = 7) and the num-
ber of HIV specific measures identified ranged from 1 to
18 (median = 11).
Quality of the reviews
The results of the quality assessment [16] are shown
in Table 3. Eight of the ten reviews clearly stated a
well formulated research question. Four of the ten re-
views had predefined and specified their inclusion and
exclusion criteria, and 4 had conducted a comprehen-
sive search including multiple scientific literature
databases and manual searches of references. None of
the reviews stated that at least two researchers had
conducted an independent review of titles, abstracts
Table 1 Search Terms
HIV Quality of Life Measurea Review
Human
Immunodeficiency Virus
QoL Inventora
PROM Scalea
Antiretrovirala Patient Reported
Outcome
Questionnairea
Self-reporta
Assessmenta
Surveya
Toola
Indicatora
Instrumenta
Notes Terms within columns were combined with ‘OR’, terms between columns
were then combined with ‘AND’
aDenotes truncation
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and full text review and indicated how disagreements
between the reviewers were resolved. No reviews
included a quality assessment. Two reviews listed the
studies they included along with descriptions of their
key characteristics. None of the reviews assessed
publication bias. The criterion ‘was heterogeneity
assessed’ [16] was not applicable because none of the
reviews included a meta-analyses.
Selection of measures for further scrutiny
Generic measures
Twenty-nine generic HRQoL measures were reviewed
against the inclusion criteria (Fig. 2). Of those, 10 were
not comprehensive, 2 were not self-administered, 7 took
longer than 10 min to complete/ had 40 or more items
and 1 had no normative data and were therefore excluded.
Nine generic measures met the inclusion criteria and were
retained for further analysis. These were the COOP/
WONCA charts [21], EQ-5D [22, 23], FLZM Questions
on Life Satisfaction [24], HUI [25], McGill Quality of life
questionnaire [26], SF-12 [27], SF-20 [28], SF-36 [29–31]
and WHOQOL-BREF [32, 33].
HIV-specific measures
Twenty-three HIV-specific HRQoL measures were reviewed
against the inclusion criteria (Fig. 3). Of those, 3 were not
Fig. 1 PRISMA Flow diagram showing paper selection process
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comprehensive, 9 took longer than 10 min to complete/
had 40 or more items and there was no evidence of patient
input in the development of 4 of the measures. Seven HIV-
specific measures therefore met the inclusion criteria and
were retained for further analysis. These were the ACTG
SF-21 [34], HIV-QL31 [35], MOS-HIV [36], MQoL-HIV
[37], PROQOL-HIV [38], WHOQOL HIV-BREF [39] and
HIV-SQUAD [40].
Overview of selected generic HRQoL measures
Properties of each of the generic HRQoL measures are
summarised in Table 4.
Fig. 2 Flow diagram showing selection of generic measures
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COOP/WONCA [21]
The COOP/WONCA charts contain 6–9 items including
the following domains: physical fitness, social activities,
feelings, change in health, daily activities and overall
health. Each item has five response options, presented
pictorially. They are available in several languages and
have been found to be acceptable to patients, however
very little psychometric data were available in the reviews
and they have not been widely used with people with HIV.
Therefore, insufficient evidence is available to determine
Fig. 3 Flow diagram showing selection of HIV-specific measures
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the suitability of this instrument for use in HIV research
or clinical practice.
EQ-5D [22, 23]
The EQ-5D consists of 5 items encompassing five di-
mensions of quality of life (mobility, self-care, usual ac-
tivities, pain/discomfort, anxiety/depression) and an
optional visual analogue scale to rate overall health. It
takes approximately 1 min to complete and is available
in multiple languages. General population preference
weights have been derived for many countries, enabling
the use of the measure in economic analyses. The re-
views provided evidence of construct and convergent
validity, as well as responsiveness to treatment initiation,
the development of opportunistic infections and adverse
effects with small to medium effect sizes [4, 10, 12, 13].
The measure has been frequently used in research with
people with HIV, and several authors recommended it
for use in this population [4, 10, 13]. However, prob-
lems with ceiling effects were noted [4, 20] therefore
the use of the scale in individuals with early, asymp-
tomatic HIV infection was not recommended [4, 19].
Wu et al. (2013) recommended the use of EQ-5D
alongside an HIV-specific measure (the MOS-HIV) in
order to obtain HIV-specific quality of life alongside
this utility measure [10].
Health utilities Index [25]
The Health Utilities Index is available in two versions
(HUI mark 2 (HUI2) and HUI mark 3 (HUI3)), which
consist of 15/16 items respectively and assess 7 do-
mains – vision, ambulation, dexterity, emotion, cogni-
tion, hearing, speech and pain. The measures are
available in multiple languages. Although the scales
have not been extensively used in HIV research, there
is some evidence for their validity in this context. HUI2
and HUI3 have been associated with disease severity,
AIDS-related events and viral load. [4, 12] Construct
validity has been established by correlating HUI scales
with the MOS-HIV [4, 20]. The scales have also been
found to be responsive to change in HIV disease states
[12, 20] however, both the MOS-HIV and EQ-5D have
been found to have better discriminatory capacity [12].
Based on emerging data, Clayson et al. (2006) consid-
ered the HUI to be a potentially useful adjuvant to an
HIV specific measure [4].
The McGill quality of life questionnaire (M-QOL) [26]
The McGill Quality of Life Questionnaire comprises 16
items encompassing four domains: support, existential
well-being, physical and psychological symptoms. Skeving-
ton et al. report that the face/content validity of the meas-
ure is improved by the inclusion of an existential
dimension, which may be particularly relevant to people
with HIV who have advanced disease (CD4 count <100)
[20]. However, only scores for one subscale (physical
symptoms) distinguished between people with HIV who
had high and low CD4 counts, indicating poor discrimin-
ant validity of the other subscales [20]. There was a lack of
information in the reviews on responsiveness or reliability.
This measure has not been frequently used with people
with HIV. There was therefore insufficient information
available to determine the suitability of this instrument.
SF-12 [27]
The SF-12 is one of three generic measures (along with
the SF-20 and SF-36) from the Medical Outcomes Study
(MOS) that met our inclusion criteria. It consists of 12
items in 8 domains: physical functioning, role-physical,
role-emotional, bodily pain, general health, vitality, social
functioning and mental health, allowing for the gener-
ation of physical and mental health summary scores.
There were little validity and reliability data available in
the reviews and mixed results were presented in terms
of responsiveness to change in treatment [12]. Since the
SF-12 shares items with other measures developed from
the MOS, it was considered likely that the scale had
similar floor and ceiling effects to other MOS scales
[17]. Clayson et al. recommended the use of the SF-12
in place of the SF-36 where the length of the SF-36 is a
problem [4].
SF-36 [29–31]
The SF-36 comprises 36 items encompassing 9 domains:
physical functioning, role-physical, bodily pain, general
health, vitality, social functioning, role-emotional, mental
health and reported health transition allowing for the
generation of physical and mental health summary
scores. The scale has been translated into several lan-
guages and takes approximately 10 min to complete.
Scores on the SF-36 can be used in economic analyses
by deriving utility weights [11]. The original SF-36 [28]
was modified to improve the range and precision of
some of the scales, improve the wording and format of
the questionnaire, resulting in the SF-36 v2 [41], how-
ever the reviews largely failed to distinguish between the
two versions. As a result, this review refers only to the
SF-36 and does not specify whether the findings relate
to Version 1 or Version 2. The reviews reported good to
acceptable internal consistency and construct validity
[13, 20]. People with HIV reported lower HRQoL on all
dimensions compared to general population controls
[13, 20]. Scale scores have been associated with treat-
ment duration, less comorbidity and better social sup-
port [13]. The SF-36 has been found to be responsive to
the initiation of ART, change in CD4 count, viral load
and symptoms [4, 12, 20] however it may not be sensi-
tive to change in ART medication in patients who are
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stable on ART [12]. Problems with floor and/or ceiling
effects have been reported on some subscales [20]. The
SF-36 was recommended for use in people with HIV in
two of the reviews [4, 18], however a criticism of this
and other MOS measures was that they were developed
in US and translated into other languages without the
input of patients to ensure conceptual and semantic
equivalence, and therefore may not be relevant for use
in cross-sectional research [20].
WHOQOL-BREF [32, 33]
The WHOQOL-BREF was developed from the WHOQOL-
100 instrument, which was produced within an inter-
national collaboration of 15 countries, using a spoke-wheel
methodology to ensure conceptual and semantic equiva-
lence across languages and cultures [20]. The instrument
has been frequently used in people with HIV. It consists
of 26 items over 4 domains: physical health, psychological
health, social relationships and environment. It is available
in 40 languages and takes less than 5 min to complete
[20]. Good psychometric properties, including Cronbach’s
alpha coefficients in the acceptable range, correlations
with disease severity and CD4 count were reported
[12, 20], however data on responsiveness were not
available in the reviews.
Two additional instruments, the FLZM [24] and the
SF-20 [28], were identified (Table 4), however the re-
views did not assess their psychometric properties.
There was insufficient information available to deter-
mine the suitability of these instruments.
Overview of selected HIV specific HRQoL measures
Properties of each of the HIV-specific HRQoL scales are
summarised in Table 5.
ACTG-SF21 [34]
The ACTG-21 consists of 21 items encompassing 7
HRQoL domains: physical functioning, energy/fatigue,
social functioning, cognition, pain, health perception and
emotional wellbeing. The reviews did not report reliabil-
ity or validity data for the scale but floor and ceiling ef-
fects were anticipated given that the scale shares items
with other MOS measures [17]. The measure has not
been widely used in people with HIV. There was there-
fore insufficient information available to determine the
suitability of this measure.
HIV-QL-31 [35]
The HIV-QL-31 is a 31-item measure encompassing the
following domains: sex life, pain, psychological aspects, re-
lationships, limitations caused by HIV, symptoms and im-
pact of treatment and care. The scale has high internal
consistency [17, 20] and has been shown to discriminate
between groups based on disease severity [20]. The meas-
ure was developed with patients and thereby covers a
broad range of issues relevant to people with HIV [20].
However the HIV-QL-31 has not been widely used and
the limited psychometric data available, including lack of
information on responsiveness, make it difficult to estab-
lish the suitability of this measure.
MOS-HIV [36]
The MOS-HIV is most widely used HIV-specific meas-
ure. Initially based on the SF-20, it consists of 35 items
across 11 domains: physical functioning, pain, social
functioning, role functioning, emotional well-being, en-
ergy/fatigue, cognitive function, health distress, health
transition, general health and overall quality of life,
allowing for the generation of physical and mental
health summary scores. The instrument has been trans-
lated into at least 14 languages. The English version
takes approximately 5–10 min to complete, but was re-
ported to take twice as long for some translations, such
as the Spanish version, where more words are required
to express the concepts [20]. Scoring and interpretation
has been described as complex [12, 20].
The reviews reported mixed findings on the psycho-
metric properties of the MOS-HIV. Good internal
consistency was generally reported [4, 12, 19, 20]
however Carabin et al. reported acceptable internal
consistency for some but not all domains [17]. Test-
retest reliability was considered inadequate [17, 19].
The reviews contained mixed findings regarding con-
struct validity, with some suggesting poor construct
validity [17] and others suggesting good construct val-
idity [20]. Acceptable convergent and discriminant val-
idity was reported in several reviews [4, 12], however
some studies did not find the expected relationship
with CD4 count [12, 20]. Responsiveness has been
established in a wide variety of contexts including ad-
verse events, increased symptoms, opportunistic infec-
tions, AIDS defining events and initiation of ART [4,
10, 12, 18, 19], however negligible effects have been
found in patients changing ART regimens [10]. Gakhar
et al. found the MOS-HIV to be more responsive than
the EQ-5D and HUI3 [12]. However, ceiling effects
have been reported on several domains [19, 20].
Overall, the MOS-HIV was considered to have well-
established psychometric properties. It was recommended
as a suitable measure for assessing HRQoL in people with
HIV [4, 10, 18], either individually or together with the
EQ-5D [10]. However reservations expressed in the re-
views included concerns about the continued relevance
of the measure for people with HIV, given that it was
one of the earliest HIV-specific scales to be developed
[4], questions about whether there was a true advantage of
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using the MOS-HIV over the SF-36 [4] and scepticism
about the ‘gold standard’ status that has been assigned to
the MOS-HIV based on available evidence [20]. One
criticism was that while patient interviews were con-
ducted as part of the development process, they had
not sampled extensively from people with HIV, limiting
content validity [20]. Furthermore, like the SF-36, the
MOS-HIV may lack conceptual relevance across differ-
ent languages and cultures [20]. The need for more in-
formation about the performance of the scale in
women, low income and disadvantaged groups was also
identified [20].
Multidimensional quality of life questionnaire for persons
with HIV/AIDS (MQOL-HIV) [37]
The MQOL-HIV consists of 40 items assessing 10
domains: physical health, physical functioning, mental
health, social functioning, cognitive functioning, social
support, financial status, sexual functioning, partner
intimacy and access to care. These domains were devel-
oped through interviews with HIV positive patients and
providers in different settings.
The MQOL-HIV was considered to be a useful instru-
ment since attention had been paid to the concerns of
people living with HIV in its development [20], however
there was limited evidence to support the construct
validity, reliability and responsiveness of this instrument
[4, 12, 20] and floor and/or ceiling effects were reported
in some domains [17].
PROQOL-HIV [38, 42]
The PROQOL-HIV consists of 43 items assessing 8 do-
mains: physical health and symptoms, treatment impact,
emotional distress, health concerns, body change, intimate
relationships, social relationships and stigma. The items
were developed through interviews conducted with people
living with HIV in 9 countries. Psychometric data were
not reported in the reviews.
Symptom quality of life adherence (HIV-SQUAD) [40]
The HIV-SQUAD consists of 24 items assessing HRQoL,
a symptom checklist and a visual analogue scale to meas-
ure adherence. Preliminary psychometric data were
reported in one review [12]. While Cronbach’s alphas
indicted acceptable internal consistency for the physical
component, there was unacceptable internal consistency
for the psychological component. The instrument was
able to discriminate between patients with different illness
states (CD4 count, hepatitis infection) and was responsive
to changes in HIV viral load [12]. However, there was no
evidence of the measure’s use beyond the initial validation
paper and limited psychometric data were available in the
reviews.
WHOQOL-HIV BREF [39]
The WHOQOL-HIV BREF was developed in focus groups
of people with HIV across 6 countries, ensuring that the
items have conceptual and semantic relevance across cul-
tures [20]. The instrument has 31 items, including several
developed as a result of input from people with HIV (e.g.
sexual activity, social inclusions and aspects of spirituality,
such as forgiveness) and covers the six generic WHOQOL
domains (physical functioning, psychological functioning,
levels of independence, social relationships, environment
and spirituality). No psychometric data on the scale were
available in the reviews.
Discussion
The aim of this review was to identify brief, appropri-
ately validated, pragmatic tools for assessing HRQoL in
HIV interventions and clinical care, by synthesising the
findings of previous reviews on this topic. Both generic
and HIV-Specific HRQoL instruments were identified.
Of the 10 generic measures, the EQ-5D, SF-36 and
WHOQOL-BREF appear to be the most extensively used
in HIV research. The reviews provided psychometric
data to support the use of the EQ-5D and SF-36. A
major advantage of the EQ-5D is its brevity, enabling
most patients to complete the instrument approximately
a minute. However, a limitation of the EQ-5D reported
in the reviews was the potential ceiling effect. Indeed in
one RCT, 40% patients obtained the highest possible
score [43]. However, the papers included all reviewed
studies using the original three level version of the EQ-
5D, whereby patients had three response options for
each item (no problems/ some or moderate problems/
extreme problems). A revised five level version is now
available (no problems/ slight problems/ moderate prob-
lems/ severe problems/ extreme problems) which has
demonstrated good psychometric qualities including ac-
ceptable internal consistency and a reduced ceiling effect
among people with HIV [44].
The benefits of these generic HRQoL instruments in-
clude the availability of normative data allowing com-
parison of HRQOL with other groups, and the ability to
examine the impact of HIV and comorbid conditions on
HRQOL in a single assessment. Furthermore utility
weights can be derived from both the EQ-5D and SF-36
enabling their use in economic analyses. However, gen-
eric measures may be less sensitive to changes in disease
or treatment than HIV-specific instruments [11].
Of the HIV-specific measures, only the MOS-HIV
was supported by sufficient psychometric data in the
reviews, although there was some concern about
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limited input from people with HIV, cultural relevance
and its continued applicability since the introduction of
ART. Two more recently developed HIV-specific mea-
sures, the WHOQOL-HIV BREF and the PROQOL-
HIV, were identified in the reviewed papers but their
psychometric properties were not described.
A paper outlining the development and initial validation
of the WHOQOL-HIV BREF was published in 2012 [39],
reporting good internal consistency and discriminant
validity. The authors highlighted the importance of the
spirituality/personal beliefs and independence domains,
often overlooked in quality of life research. They acknowl-
edged the need for further validation, including in studies
with longitudinal designs. Subsequent cross-sectional re-
search has provided evidence of the measure’s psychomet-
ric properties in a range of populations including people
with HIV in Portugal [45, 46], Taiwan [47], Malaysia [48],
Vietnam [49] and Iran [50]. Preliminary evidence of its re-
sponsiveness comes from a prospective study of patients
initiating ART in China, where significant improvements
in QOL in all WHOQOL-HIV BREF domains were ob-
served over the first six months of treatment [51].
The PROQOL-HIV was developed with extensive input
from people living with HIV across nine countries [38]. It
has been validated in a large cross-sectional multi-cultural
study, demonstrating good internal consistency and con-
struct validity [42]. In addition, satisfactory test-retest reli-
ability has been established in a smaller sample [42]. An
electronic version of the PROQOL-HIV has been found
to be reliable and acceptable to patients [52]. Again, there
is currently limited published research assessing the re-
sponsiveness of the PROQOL-HIV, although a recent trial
reported a significant increase in scores on the body
change, social relationships and emotional distress sub-
scales following an online self-management intervention
[53]. The PROQOL-HIV and WHOQOL-HIV BREF are
increasingly being used in HIV research and may prove to
be psychometrically sound and culturally valid alternatives
to the MOS-HIV.
One strategy recommended within the reviews was to
use a generic measure alongside an HIV-specific instru-
ment [4, 10], such as the EQ-5D and the MOS-HIV
[10]. Due to overlap in items it would not be appropriate
to use the SF-36 alongside the MOS-HIV [4].
This review adds value to the literature by synthesising
the findings of existing reviews of HRQoL measures used
in HIV, including the findings of recent reviews on the
subject [3, 10–12] which had various aims, for example to
identify frequently used instruments [3]; determine how
instruments have been applied to ART utilisation [12],
identify measures used in a specific treatment context [11]
and determine the responsiveness of specific instruments
[10]. As with all reviews, we were limited by the data
available in the included papers. The results of the quality
assessment indicated that many of the reviews were of a
poor quality, with most lacking a comprehensive search
or identification/selection of papers by independent re-
viewers. No recent reviews with searches conducted
since 2013 were identified. It is possible that new mea-
sures of quality of life could have been validated for use
in people with HIV since this time. For example, a
shorter version of the WHOQOL- BREF has subse-
quently been developed (EUROHIS-QOL-8) [54] but as
yet there are insufficient validation data to recommend
this measure.
For this review our aim was to identify brief measures
for use in a busy clinic or repeated measures study.
However, there may be HRQoL tools available that take
longer than 10 min to complete or have more than 40
items but are still acceptable to patients and clinicians
in the HIV care setting. For example the Functional As-
sessment of Human Immunodeficiency Virus Infection
(FAHI [55]; 47 items, <15mins completion time [4, 56])
was viewed favourably in the review by Clayson and
colleagues [4] and may be appropriate, although others
have suggested it is too long and difficult to score for
use in a clinical setting [57]. Further research is re-
quired to establish acceptability, which was rarely men-
tioned in the reviews. The selection of a HRQoL
measure for use in research or clinical practice is also
likely to be influenced by cost and the need to buy a li-
cence. The reviews included in this review did not include
information on the cost of the various instruments, there-
fore no licencing or cost information has been included in
the current review.
The choice of one HRQoL measure over another is
likely to be influenced by the purpose of the quality of
life assessment and the domains of HRQoL that are
most relevant to the specific research or clinical ques-
tion. For example, responsiveness is essential where the
aim is to evaluate treatment. Our review provided evi-
dence of responsiveness for the EQ-5D, SF-36 and
MOS-HIV. For clinical practice, it is important that a
wider range of requirements are met, for example it is
important that the scale is valid and reliable, but also
simple to complete and score and easily interpretable
[58]. The MOS-HIV and SF-36 include several different
rating scales and response options, which could make
scoring complex [20]. While psychometric data were
lacking in the reviews, subsequent research suggests
that the WHOQOL-HIV BREF and PROQOL-HIV may
prove to be the most cross-culturally valid measures
and therefore a good choice for international assess-
ment of HRQOL in HIV.
Conclusion
This systematic review of reviews identified several
validated generic and HIV specific pragmatic tools for
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assessing HRQoL in HIV interventions and clinical
care. The measures supported with most psychometric
evidence in the systematic reviews were the EQ-5D,
SF-36, WHOQOL-BREF and MOS-HIV. More recently
developed HIV specific scales, including the PROQOL HIV
and WHOQOL BREF-HIV may prove to be the most
cross-culturally valid. Ultimately, the selection of a HRQoL
measure is likely to be influenced by the context in which it
is to be used.
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